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Ethnopharmacological  relevance:  Aloysia  gratissima  (Gill.  et Hook)  Tronc.  (Verbenaceae)  is  used
traditionally  for  the  treatment  of  headache,  bronchitis,  and  nervous  systems  disorders  including
depression.
Aim  of the  study:  To  investigate  the  antidepressant-like  and  neuroprotective  effects  of Aloysia  gratissima
aqueous  extract  (AE)  and  the involvement  of  l-arginine-nitric  oxide  (NO)-cyclic  guanosine  monophos-
phate  (cGMP)  pathway.
Materials  and methods:  The  antidepressant-like  effect  of  AE was  evaluated  through  behavioral  despair
in  forced  swimming  test  (FST)  and  tail  suspension  test  (TST).  Swiss  albino  mice  were  treated  by  oral
route  and  after  1 h were  analyzed  the  time  of immobility  in  the  FST  and  TST.  In  addition,  the  neuropro-
tective  effect  of AE  against  glutamate  excitotoxicity  was  evaluate  through  cell  viability  of hippocampal
slices,  phosphorylation  of  Akt,  and  the  immunocontent  of  inducible  oxide  nitric  synthase  (iNOS)  were
investigated  by  western  blotting.
Results:  The  immobility  time  in  the  FST  and  TST  were  reduced  by  AE  (100–1000  and  10–300  mg/kg,
respectively).  The  antidepressant-like  effect  of  AE in  the  TST  was  prevented  by  the  pretreatment  with
N-methyl-d-aspartate  (NMDA),  l-arginine  or sildenaﬁl.  The  subeffective  dose  of AE produced  a  syner-
gistic  antidepressant-like  effect  with  MK-801  (an  antagonist  of  NMDA  receptor),  methylene  blue,  l-NNA
(an inhibitor  of  NO  synthase)  or  ODQ  (an  inhibitor  of  soluble  guanylate  cyclase).  In  ex vivo experiments,
pretreatment  with  AE  prevented  the  loss  of  cell  viability  induced  by glutamate,  thus  affording  neuropro-
tection.  Glutamate  toxicity  caused  a  decreased  Akt phosphorylation  and  an  increased  iNOS  expression.
Conclusions:  The  present  study  provides  convincing  evidence  of neuroprotection  and  the  involvement
of  the  l-arginine-NO-cGMP  pathway  in the  antidepressant-like  effect  of  AE.  Therefore,  AE  could  be  of
potential  interest  for the  treatment  of  depressive  disorders  and neurological  conditions  associated  with
glutamate  excitotoxicity.
. IntroductionAloysia gratissima (Gill. et Hook) Tronc. is an aromatic native
lant belonging to Verbenaceae family which is widely distributed
Abbreviations: AE, Aloysia gratissima aqueous extract; cGMP, cyclic guano-
ine monophosphate; FST, forced swimming test; MK-801, (+)-5-methyl-
0,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate; MTT, (3-(4,5-
imethylthiazol-2-yl-diphenyltetrazolium bromide; NMDA, N-methyl-d-aspartate;
-NNA, NG-nitro-l-arginine; NO, nitric oxide; NOS, nitric oxide synthase; ODQ,
H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one; PDE5, phosphodiesterase-5; TST, tail
uspension test.
∗ Corresponding author. Tel.: +55 48 3721 5046; fax: +55 48 3721 9672.
E-mail address: tasca@ccb.ufsc.br (C.I. Tasca).
378-8741 © 2011 Elsevier Ireland Ltd. 
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Open access under the Elsevier OA license. © 2011 Elsevier Ireland Ltd. 
in subtropical regions of South America, mainly Brazil, Uruguay,
Paraguay, and Argentina. In Brazil it is popularly named “erva
santa”, “erva de nossa senhora” and “garupá”, among others. The
aerial parts of this plant species are used for the treatment of
headache, bronchitis and nervous systems disorders (Souza and
Wiest, 2007), digestive and depression (Vendruscolo et al., 2005;
Arias Toledo, 2009).
In other species of Aloysia, i.e., Aloysia polystachya, the hydro-
ethanolic extract of aerial parts has been shown to exhibit
anxiolytic (Hellión-Ibarrola et al., 2006) and antidepressant-like
Open access under the Elsevier OA license. effects in mice (Hellión-Ibarrola et al., 2008) and in rats (Mora et al.,
2005). Two active diterpenes were isolated from the aerial parts of
Aloysia virgata exhibiting anxiolytic-like effect in mice (Wasowski
and Marder, 2011). However, to the best of our knowledge, there is
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o scientiﬁc report related to antidepressant-like effects of Aloysia
ratissima.
The essential oil of leaves of Aloysia gratissima has been reported
o exhibit virucidal (García et al., 2003), nematicidal (Duschatzky
t al., 2004), and fungicidal (Dellacasa et al., 2003) activities. The
thanolic extract of aerial parts of Aloysia gratissima presents
hemical compounds such as kauranes, ﬂavonoids and
henylethanoids (Silva et al., 2006), and sesquiterpens (-
isabolol), triterpens (-amirin, betulinic acid, oleanoic acid,
nd ursolic acid), and ﬂavonoids (genkwanin, 5-hydroxy-7,4′-
imethoxyapigenin, 5-hydroxy-7,3′,4′-trimethoxyluteolin and
utin) were found in the methanolic extract of leaves (Vandresen
t al., 2010). The methanolic extract showed antibacterial and
ntiedematogenic properties (Vandresen et al., 2010) and also
ntioxidant effect as documented by Rosas-Romero and Saavedra
2005).
Depressive disorders have high incidence in the world popula-
ion (Berton and Nestler, 2006), with impact in the social function
nd in the life quality of patients (Nemeroff, 2007). The treatment
f depression with conventional antidepressants (monoamine oxi-
ase inhibitors, tricyclics, selective serotonin reuptake inhibitors,
elective noradrenaline reuptake inhibitors) provides a com-
lete remission just for 50% of the individuals (Rush et al.,
003) and antidepressant therapy produces side effects (Brunello
t al., 2002) that may  reduce the adhesion of patients to treat-
ent (MacGillivray et al., 2003). Therefore, additional treatment
trategies with favorable side effects proﬁle, credible beneﬁts,
nd moderate costs are of particular interest (Laakmann et al.,
998).
In the search of new molecules useful for the treatment of
eurological disorders, medicinal plant research worldwide has
rogressed constantly, demonstrating the pharmacological effec-
iveness of different plant species in a variety of animal models
Zhang, 2004). Plant extracts – including St. John’s worth – have
een used for the treatment of some psychiatric disorders that is
argely studied for the treatment of depression (Linde and Knuppel,
005) and Ginkgo biloba (Sakakibara et al., 2006).
Although the monoaminergic system has been widely stud-
ed regarding the mechanism of action of antidepressants, the
lutamatergic system has been proposed as an important tar-
et for the action of novel antidepressant agents (Skolnick, 1999;
anacora et al., 2008). Noteworthy, targeting NMDA receptor block-
de, particularly with the administration of the NMDA receptor
ntagonist ketamine produces improvement of the depressive
ymptoms much faster than conventional monoaminergic agents
n patients resistant to conventional drug treatment strategies
Zarate et al., 2006; Maeng and Zarate, 2007; Sanacora et al.,
008). NMDA receptor stimulation induces the activation of nitric
xide synthase (NOS) that converts l-arginine to NO and l-
itrulline (Esplugues, 2002). It has been also demonstrated that
OS inhibitors exert antidepressant-like effects in depression mod-
ls (Dhir and Kulkarni, 2007; Ulak et al., 2008). Moreover, several
tudies suggest that the inhibition of NO synthesis, with a
ubsequent decrease in the concentration of cGMP, produce
ntidepressant-like effects (Kaster et al., 2005). Noteworthy, the
MDA receptors and the l-arginine-nitric oxide (NO)-cGMPc
athway are promising molecular targets for the action of antide-
ressant drugs.
Therefore, this study was aimed, ﬁrstly, to examine the effects
f the oral administration of AE in two predictive models of antide-
ressant activity, the forced swimming test (FST) and the tail
uspension test (TST). Secondly experiments were performed to
nvestigate a possible participation of the l-arginine-NO-cGMP
athway in the antidepressant-like effect of Aloysia gratissima in the
ST. Furthermore, this study analized, by using an ex vivo approach,
he ability of AE treatment to counteract hippocampal glutamatemacology 137 (2011) 864– 874 865
excitotoxicity and the involvement of Akt phosphorylation and
iNOS expression in the neuroprotection afforded by AE.
2. Materials and methods
2.1. Animals
Swiss male mice weighing 30–40 g were maintained at 21–23 ◦C
with free access to water and food under a 12 h light/dark cycle
(lights on at 7:00 h-am). All the manipulations were carried out
between 9:00 and 16:00 h, with each animal used only once. These
experiments were performed after approval of the protocol by the
Ethics Committee of the Institution and all efforts were made to
minimize animal suffering.
2.2. Plant material
2.2.1. Botanic material
The aerial parts of Aloysia gratissima (Gill. et Hook) Tronc. were
collected from the boundaries of Serra do Itajaí National Park,
Guabiruba city, Santa Catarina state, Brazil in autumn, 2006. The
plant material was identiﬁed and authenticated taxonomically at
Regional University of Blumenau. A voucher speciment (#2658)
of the collected was  deposited in the Dr. Roberto Miguel Klein
Herbarium for future reference.
2.2.2. Preparation of extract
Aerial parts of Aloysia gratissima were washed, and then
the dried material was  powered. The powered material (2.5 g)
was  extracted with boiling water (150 ml)  for 5 min. The aque-
ous extract of Aloysia gratissima (AE, yield 25.71%) was ﬁltered,
lyophilized, stored in freezer at −20 ◦C and resolubilized in distilled
water at the time of administration.
2.3. Drugs and treatment
The following drugs were used: l-arginine, l-glutamate, NG-
nitro-l-arginine (l-NNA), methylene blue, MK-801, NMDA, (1H-
[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one) (ODQ) (Sigma Chemical
Co, USA) and sildenaﬁl citrate (Pﬁzer). All drugs were dissolved
in saline, except ODQ which was dissolved in vehicle with 1%
DMSO and 7-nitroindazole that was  dissolved in vehicle with few
drops of Tween-80. All drugs were administered by intraperitoneal
(i.p.) route in a constant volume of 10 ml/kg body weight, except
NMDA and ODQ which were administered by intracerebroventric-
ular (i.c.v.) route. AE was also administered by oral (p.o.) route
by gavage in a volume of 10 ml/kg body weight. Animals were
restricted from food 1 h before and after the AE administration.
I.c.v. administration was performed using a microsyringe
(25 l, Hamilton) connected to a 26-gauge stainless-steel needle
that was  inserted perpendicularly 2 mm  deep through the skull
according to the procedure originally described by Laursen and
Belknap (1986).  Brieﬂy, the animals were anesthetized with ether
and then gently restrained by hand for i.c.v. injections. The
sterilization of the injection site was  carried out using gauze
embedded in 70% ethanol. Under light anesthesia (i.e. just that
necessary for loss of the postural reﬂex), the needle was inserted
unilaterally 1 mm to the midline point equidistant from each eye, at
an equal distance between the eyes and the ears and perpendicular
to the plane of the skull. A volume of 5 l of sterile saline contain-
ing the drugs was  injected directly into the lateral ventricle, at the
following coordinates from bregma taken from the atlas of Franklin
and Paxinos (2001) anterioposterior (AP) = −0.1 mm;  mediolateral
(ML) = 1 mm;  and dorsoventral (DV) = −3 mm.  Mice exhibited nor-
mal  behavior within 1 min  after injection. After completion of the
experiments, all animals were decapitated and their brains were
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xamined freshly. Results from mice presenting misplacement of
he cannula or any sign of cerebral hemorrhage were excluded from
he statistical analysis (overall less than 5% of the total animals
sed).
The AE was dissolved in distilled water and administered acutely
y oral route (p.o.) 60 min  before the FST (30–1000 mg/kg, p.o.),
ST (3–1000 mg/kg, p.o.) or open-ﬁeld test. The dissolution of the
xtract was freshly done from the lyophilized power immediately
efore its administration by gavage. A control group received dis-
illed water as vehicle. In the experiments designed to study the
ime–course effect of AE (10 mg/kg, p.o.), the immobility time in
he TST and the number of crossings in the open-ﬁeld test were
ssessed in an independent group of mice, 1 h, 2 h, 4 h, and 12 h out
fter the administration of AE (10 mg/kg, p.o.).
To test the hypothesis that the antidepressant-like effect AE is
ediated through the inhibition of NMDA receptors, mice were
retreated with NMDA (0.1 pmol/site, i.c.v.) and 15 min  after, AE
10 mg/kg) or vehicle was administered. 60 min  later the TST was
arried out. The dose of NMDA was chosen based on previous stud-
es (Brocardo et al., 2008; Zomkowski et al., 2010).
In another set of experiments, we investigated the synergistic
ffect of a sub-effective dose of AE (3 mg/kg, p.o.) with a sub-
ffective dose of MK-801 (0.001 mg/kg, i.p., a non-competitive
MDA receptor antagonist). AE or vehicle was administered 30 min
efore MK-801. A further 30 min  were allowed to elapse before the
nimals were tested in the TST.
To investigate whether the antidepressant-like effect of AE is
ediated through the involvement of the l-arginine-NO pathway
n the TST, mice were pretreated with l-arginine, a precursor of
itric oxide (750 mg/kg, i.p., a dose that produces no effect in the tail
uspension test). 30 min  after l-arginine, AE (10 mg/kg) or vehicle
as administered, and 60 min  later the TST was carried out.
In another experiment, we also investigated the effect of AE
3 mg/kg, a sub-effective dose) with sub-effective doses of l-NNA
0.3 mg/kg, i.p., a competitive inhibitor of NO synthase with selec-
ivity for the neuronal and endothelial isoforms of the enzyme),
ethylene blue (20 mg/kg, i.p., an inhibitor of both NO synthase and
oluble guanylate cyclase) or ODQ (30 pmol/site i.c.v., a selective
nhibitor of soluble guanylate cyclase). AE or vehicle was adminis-
ered 30 min  before the drugs and 30 min  later the animals were
ested in the TST.
To investigate the role of cyclic GMP  (cGMP) in the
ntidepressant-like action of AE, mice received an injection of silde-
aﬁl (5 mg/kg, i.p., a phosphodiesterase 5 inhibitor), or vehicle,
0 min  before AE (10 mg/kg), and a further 30 min  elapsed before
he animals were tested in the TST. The dose of sildenaﬁl was  cho-
en based on previous studies (Kaster et al., 2005; Almeida et al.,
006; Dhir and Kulkarni, 2007; Zomkowski et al., 2010).
.4. Forced swimming test (FST)
For the FST mice were individually forced to swim in an open
ylindrical container (diameter 10 cm,  height 25 cm), containing
9 cm of water at 25 ± 1 ◦C; the total duration of immobility dur-
ng a 6 min  test was scored as described previously by Kaster et al.
2005). Each mouse was judged to be immobile when it ceased
truggling and remained ﬂoating motionless in the water, making
nly those movements necessary to keep its head above water.
.5. Tail suspension test (TST)
The tail suspension test has become one of the most widely
sed models for assessing antidepressant-like activity in mice. The
est is based on the fact that animals subjected to the short-term,
nescapable stress of being suspended by their tail, will develop
n immobile posture. The total duration of immobility induced bymacology 137 (2011) 864– 874
tail suspension was measured according to the method described
by Steru et al. (1985).  Brieﬂy, mice both acoustically and visu-
ally isolated were suspended 50 cm above the ﬂoor by adhesive
tape placed approximately 1 cm from the tip of the tail. Immobility
time was  recorded during a 6 min  period (Rodrigues et al., 2002;
Machado et al., 2007). Mice were considered immobile only when
they hung passively and completely motionless. The immobility
time was  recorded by an observer blind to the drug treatment.
2.6. Open-ﬁeld test
The forced swimming test has some drawbacks represented
by the possibility of obtaining false positives or negatives. Drugs
enhancing locomotor activity can evoke a ‘false’ positive effect in
these tests, whereas drugs decreasing locomotion may  give a ‘false’
negative result (Borsini and Meli, 1988). Therefore, in order to rule
out an interference of the locomotor activity in the interpreta-
tion of the results obtained in the immobility tests, the locomotor
activity was  measured in the open-ﬁeld test as described previously
(Zomkowski et al., 2010). The open ﬁeld arena used was a wooden
box (40 cm ×60 cm ×50 cm)  with the ﬂoor divided into 12 equal
squares. At the start of each trial a mouse was  placed in the left
corner of the ﬁeld and was  allowed to freely explore the arena. The
number of squares crossed with all paws (crossing) was counted
in a 6 min  session. The arena ﬂoor was  cleaned between the tri-
als with a 10% ethanol solution and the test was carried out in a
temperature, noise and light controlled room.
2.7. Ex vivo neurochemical experiments
2.7.1. Treatment of mice with AE and preparation of hippocampal
slices
The AE (10, 30 and 100 mg/kg) was administered by gavage
and after 1 h mice were killed by decapitation and the hippocam-
pus was  rapidly removed and placed in ice-cold Krebs–Ringer
bicarbonate (KRB) buffer (122 mM NaCl, 3 mM KCl, 1.2 mM
MgSO4, 1.3 mM CaCl2, 0.4 mM KH2PO4, 25 mM NaHCO3
and 10 mM d-glucose). The buffer was bubbled with
95% O2–5% CO2 up to pH 7.4. Slices (0.4 mm thick)
were rapidly prepared using a McIlwain Tissue Chopper,
separated in KRB at 4 ◦C and allowed to recover for 30 min  in
KRB at 37 ◦C (Oliveira et al., 2002).
2.7.2. Slices incubation
Hippocampal slices were incubated with glutamate (10 mM)
(Sigma) for 1 h in KRB. After this period, the medium was with-
drawn and replaced by a nutritive incubation medium composed
of 50% of KRB, 50% of Dulbecco’s modiﬁed Eagle’s medium (DMEM,
Gibco), 20 mM  HEPES, and 100 g/ml gentamicin, at 37 ◦C in a CO2
atmosphere for additional 6 h in order to evaluate cell viability
(Molz et al., 2008).
2.7.3. Evaluation of cell viability
2.7.3.1. MTT  reduction. Hippocampal cell viability was evalu-
ated 6 h after glutamate exposure. Cell viability was determined
through the ability of cells to reduce MTT  (3-(4,5-dimethylthiazol-
2-yl-diphenyltetrazolium bromide; Sigma) (Mosmann, 1983).
Hippocampal slices were incubated with MTT (0.5 mg/ml) in KRB
for 30 min  at 37 ◦C. The tetrazolium ring of MTT  can be cleaved by
active dehydrogenases in order to produce a precipitated formazan.
The formazan produced was  solubilized by adding DMSO, resulting
in a colored compound whose optical density was  measured in an
ELISA reader (550 nm).
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Fig. 1. Effect of Aloysia gratissima (AE) (3–1000 mg/kg, p.o.) in the FST (A), in the
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Fig. 2. Time–course effect of the oral administration of EA (10 mg/kg) in the immo-
bility time in the TST (A) and on the number of crossings in the open-ﬁeld test (B)
behavior in mice. AE was  administered 1, 2, 4 or 12 h before the test. Values are
expressed as mean ± S.E.M (n = 6–7). **P < 0.01,*P  < 0.05 compared with the vehicle-ST  (B) and in the open-ﬁeld test in mice (C). Values are expressed as mean ± S.E.M.
n  = 6–11). *P < 0.05; **P < 0.01 as compared with the vehicle-treated control.
.7.4. Western blot analysis
Slices were solubilized with a SDS-sample solution (4% SDS,
 mM EDTA, 8% -mercaptoethanol, and 50 mM  Tris, pH 6.8). Sam-
les (60 g of total protein/track) were separated by SDS-PAGE
sing a 10% gel. The amount of protein loading was  controlled by
onceau staining of the nitrocellulose membranes. Proteins sepa-
ated by SDS-PAGE were transferred to nitrocellulose membranes
sing a 350 mA,  100 V current (1 h, 4 ◦C) (Molz et al., 2008). The
embranes were blocked with 5% slim-milk (1 h) in TBS (10 mM
ris, 150 mM NaCl, pH 7.5). All steps were followed by three times
ashing with TBS-T (0.05% Tween-20, 10 mM  Tris, 150 mM NaCl,
H 7.5). Primary antibodies were selective for phospho-Akt and
otal-Akt (Sigma, 1:1000), iNOS (Santa Cruz Biotech, 1:10,000),
nd -actin (Santa Cruz Biotech, 1:2000). Immunocomplexes were
isualized using the ECL detection system as recommended by the
anufacturer. The optical density of bands was quantiﬁed by using
he Scion Image software (Scion Corporation).
.7.5. Measurement of protein content
Protein content was evaluated by the method of Peterson (1977)
n samples diluted in SDS solution. Bovine serum albumin (Sigma)
as used as standard.treated control group.
2.8. Statistical analysis
In the behavioral experiments, comparisons among treatment
groups and control were performed by one-way or two-way
ANOVA followed by Tukey’s test, when appropriate. In the ex vivo
experiments a one-way ANOVA was  used followed by Duncan’s
test, when appropriate.
3. Results
3.1. Effect of acute treatment with AE on the immobility time in
the FST, TST and locomotor activity in the open-ﬁeld test
The effect of the acute administration of AE on the immobility
time in the FST and TST is shown in Fig. 1A and B, respectively.
The administration of 30 mg/kg of AE was  ineffective to reduce
the immobility time, as compared to control mice. The treatment
of mice with AE (effective dose range: 100–1000 mg/kg) by p.o.
route signiﬁcantly decreased the immobility time in the FST (F
5,39 = 17.38, P < 0.01).
AE also caused a reduction in the immobility time in the
TST when administered by p.o. route (effective dose range:
10–300 mg/kg) (F 7,47 = 8.34, P < 0.01). However, the administra-
tion of lower (3 mg/kg) and higher (600 or 1000 mg/kg) doses of
AE was  ineffective to reduce the immobility time, showing a bell-
shaped curve effect for AE in the TST. AE did not produce any change
in ambulation in an open-ﬁeld test in all doses tested (F 7,52 = 1.89,
P = 0.09) in a separate experiment as compared to the control group
(Fig. 1C).
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Pig. 3. Effect of the pretreatment of mice with NMDA (0.1 pmol/site, i.c.v.) on the an
ombination with a sub-effective dose of AE (3 mg/kg, p.o.) in the TST (A and C, res
alues  are expressed as mean ± S.E.M. (n = 6–7). **P < 0.01 compared with the vehic
.2. Time–course effect of AE on the immobility time in the TST
nd locomotor activity in the open-ﬁeld test
The time–course effect of the oral administration of AE on the
mmobility time in the TST is shown in Fig. 2A. The treatment of
ice with AE (10 mg/kg, p.o.) produced a marked effect in the TST as
arly as 1 h after its administration, an action that remained statisti-
ally signiﬁcant until 4 h after its administration. Two-way ANOVA
howed a signiﬁcant effect of AE (AE treatment: F 1,43 = 78.49,
 < 0.01 and interaction AE treatment × time period: F 3,43 = 4.14,
 < 0.05, but not time period: F 3,43 = 1.21, P = 0.32) in the TST.
ig. 2B shows no changes were observed in the locomotor activity
f mice as compared to the control group (Treatment: F 1,42 = 2.25,
 = 0.14; time: F 3,42 = 10.68, P < 0.01; interaction treatment × time:
 3,42 = 0.44, P = 0.72). Moreover, post hoc analysis showed that AE
xhibits similar effect at 1 or 2 h, however its antidepressant-like
ffect was diminished at 4 h and no longer observed at 12 h.
Since 10 mg/kg of the AE was the lowest acute effective dose
1 h before behavioral analysis), all the experiments regarding the
nvestigation of the mechanisms underlying the antidepressant-
ike effect of the extract were performed in the TST using this dose.
.2.1. Effect of treatment of mice with NMDA or MK-801 on the
ntidepressant-like effect of AE in the TSTFig. 3A shows that the pretreatment of mice with NMDA
0.1 pmol/site, i.c.v.) was able to reverse the antidepressant-like
ffect of AE (10 mg/kg, p.o.) in the TST (Pretreatment: F 1,20 = 8.40,
 < 0.01; treatment: F 1,20 = 4.03, P = 0.06; interaction pretreat-mobility action of AE (10 mg/kg, p.o.) or treatment of MK-801 (0.001 mg/kg, i.p.) in
ely) and on the number of crossings in the open-ﬁeld test (B and D, respectively).
ted control; #P < 0.01 compared with the same group pretreated with vehicle.
ment × treatment: F 1,20 = 16.29, P < 0.01). The administration of
NMDA alone or in combination with AE did not affect the ambu-
lation in the open-ﬁeld (Fig. 3B) (pretreatment: F 1,20 = 0.10,
P = 0.75; treatment: F 1,20 = 0.74, P = 0.38; interaction pretreat-
ment × treatment: F 1,20 = 0.01, P = 0.96).
Fig. 3C shows that MK-801 (0.001 mg/kg, i.p.) in combina-
tion with a sub-effective dose of AE (3 mg/kg; p.o.) produced an
antidepressant-like effect in the TST (pretreatment: F 1,20 = 8.40,
P < 0.01; treatment: F 1,20 = 4.03, P = 0.06; interaction pretreat-
ment × treatment: F 1,20 = 16.29, P < 0.01). The administration of
MK-801 alone or in combination with AE did not affect the ambu-
lation in the open-ﬁeld (Fig. 3D) (pretreatment: F 1,20 = 0.10,
P = 0.75; treatment: F 1,20 = 0.74, P = 0.38; interaction pretreat-
ment × treatment: F 1,20 = 0.01, P = 0.96).
3.2.2. Effect of pretreatment with l-arginine on the AE induced
anti-immobility effect in the TST
The results depicted in Fig. 4A shows that the pretreatment with
l-arginine (750 mg/kg i.p., a nitric oxide precursor) prevented the
antidepressant-like effect of AE (10 mg/kg, p.o.) in the TST (pre-
treatment: F 1,20 = 4.73, P < 0.05; treatment: F 1,20 = 25.68, P < 0.01;
interaction pretreatment × treatment: F 1,20 = 1.46, P < 0.01). The
administration of l-arginine alone or in combination with AE did
not affect the ambulation in the open-ﬁeld (Fig. 4B) (pretreatment:
F 1,20 = 0.01, P = 0.91; treatment: F 1,20 = 0.04, P = 0.84; interaction
pretreatment × treatment: F 1,20 = 1.07, P = 0.31).
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Fig. 4. Effect of the pretreatment of mice with l-arginine (750 mg/kg, i.p.; A) on the
anti-immobility action of AE (10 mg/kg, p.o.) in the TST (A) and on the number of
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*P  < 0.01 compared with the vehicle-treated control; #P < 0.01 compared with the
ame group pretreated with vehicle.
.2.3. Effects of combined administration of sub-effective doses of
he NOS and soluble guanylate cyclase inhibitors and AE in the TST
r in the open-ﬁeld test
Fig. 5A shows that l-NNA (0.3 mg/kg, i.p., a NOS inhibitor) in
ombination with AE (3 mg/kg, p.o.) produced an anti-immobility
ffect in the TST as compared with the administration of
ither drug alone (pretreatment: F 1,20 = 5.87, P < 0.05; treatment:
 1,20 = 19.46, P < 0.01; interaction pretreatment × treatment: F
,20 = 14.49, P < 0.01). The administration of l-NNA alone or in
ombination with AE did not affect the ambulation in the open-
eld (Fig. 5B) (pretreatment: F 1,24 = 3.03, P = 0.09; treatment:
 1,24 = 0.31, P = 0.58; interaction pretreatment × treatment: F
,24 = 0.03, P = 0.86).
Fig. 5C shows that methylene blue (20 mg/kg, i.p., direct
nhibitor of both nitric oxide synthase and soluble guanylate
yclase) in combination with AE (3 mg/kg, p.o.) also produced
n anti-immobility effect in the TST as compared with the
dministration of either drug alone. The administration of methy-
ene blue (20 mg/kg, i.p.) alone (pretreatment: F 1,23 = 5.82,
 < 0.05; treatment: F 1,23 = 18.22, P < 0.01; interaction pretreat-
ent × treatment: F 1,23 = 13.1, P < 0.01) or in combination with
E did not affect the ambulation in the open-ﬁeld (Fig. 5D) (pre-
reatment: F 1,24 = 1.72, P = 0.20; treatment: F 1,24 = 0.32, P = 0.58;
nteraction pretreatment × treatment: F 1,24 = 0.56, P = 0.46).
The results illustrated in Fig. 5E show the administra-
ion of ODQ (30 pmol/site i.c.v., a selective guanylate cyclasemacology 137 (2011) 864– 874 869
inhibitor) in combination with AE (3 mg/kg, p.o.) produced an
antidepressant-like effect as compared with the administration of
either drug alone (pretreatment: F 1,24 = 34.15, P < 0.01; treatment:
F 1,24 = 38.48, P < 0.01; interaction pretreatment × treatment: F
1,24 = 24.77, P < 0.01). Fig. 5F shows that the administration of ODQ
alone or in combination with AE did not affect locomotor activity
in the open-ﬁeld test (Pretreatment: F 1,24 = 1.09, P = 0.31; treat-
ment: F 1,24 = 0.81, P = 0.38; interaction pretreatment × treatment:
F 1,24 = 3.77, P = 0.06).
3.2.4. Effects of pretreatment with sildenaﬁl in the
antidepressant-like effect of AE
Fig. 6A shows that the anti-immobility effect of AE (10 mg/kg,
p.o.) was  completely prevented by pretreatment of animals with
sildenaﬁl (5 mg/kg, i.p., an inhibitor of phosphodiesterase 5, PDE5),
which per se produced no effect in the TST (pretreatment: F
1,20 = 14.32, P < 0.01; treatment: F 1,20 = 17.03, P < 0.01; interaction
pretreatment × treatment: F 1,20 = 10.91, P < 0.01). The administra-
tion of sildenaﬁl (5 mg/kg, i.p.) alone or in combination with AE did
not affect the locomotor activity in the open-ﬁeld (Fig. 6B) (pre-
treatment: F 1,20 = 0.51, P = 0.48; treatment: F 1,20 = 0.44, P = 0.51;
interaction pretreatment × treatment: F 1,20 = 2.43, P = 0.13).
3.3. Neuroprotective effect of AE against glutamate-induced
toxicity
The incubation of hippocampal slices for 1 h with gluta-
mate (10 mM,  in vitro) signiﬁcantly reduced the cell viability,
assessed by MTT  reduction, when compared to control slices.
Glutamate-induced hippocampal slice damage was  not observed
in hippocampal slices obtained from mice previously treated (1 h
before decapitation of mice and slices preparation) with AE as an
ex vivo evaluation of the neuroprotective effect of AE (10 mg/kg)
(Fig. 7).
3.4. AE prevents glutamate-induced decreased of Akt
phosphorylation and increase of iNOS immunocontent
Fig. 8 shows that glutamate induced a decrease in Ser-473Akt
phosphorylation in hippocampal slices obtained from mice previ-
ously treated with vehicle (ex vivo experiment). On the contrary,
glutamate was unable to cause this effect in slices obtained from
mice previously treated with AE (10 mg/kg, p.o., 1 h before slices
preparation). These results suggest that the activation of the
PI3K/Akt pathway is implicated in the protection afforded by AE.
No signiﬁcant alteration was observed in total Akt protein immuno-
content.
In addition, Fig. 9 shows a glutamate-induced increase in the
iNOS expression in hippocampal slices obtained from mice previ-
ously treated with vehicle. Also, glutamate was unable to cause
this effect in slices obtained from mice previously treated with AE
(10 mg/kg, p.o., 1 h before slices preparation).
4. Discussion
In the present study, we demonstrated for the ﬁrst time that
acute AE orally administered is effective in producing signiﬁcant
antidepressant-like effect in FST and TST, without modifying the
motor performance of mice. Moreover, an ex vivo evaluation of glu-
tamatergic toxicity in hippocampal slices obtained from pretreated
mice showed that AE is also neuroprotective to hippocampal dam-
age induced by glutamate.
The FST and TST are widely accepted stress models of depres-
sion used to screen new antidepressant drugs, as they are
sensitive to all major classes of antidepressant drugs including
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ST  in mice (A, C and E, respectively) and in the open-ﬁeld test (B, D, and F, resp
ehicle-treated control group.
ricyclics, serotonin-selective reuptake inhibitors, monoamine oxi-
ase inhibitors, and atypical (Porsolt et al., 1977; Steru et al.,
985). However, these tests do not have an identical neuro-
hemical basis (Bai et al., 2001). Therefore, the fact that AE
dministration is active in both tests reinforces the assumption
hat AE might play a role in the modulation of depression. How-
ver, AE caused a biphasic (‘bell-shaped’) dose–response curve
n the TST, but did not produce this effect in the dose range
ested in the FST. Indeed, a bell-shaped dose–response proﬁle for
everal compounds has been reported in the TST, such as for 5,6-
ibromo-N,N-dimethyltryptamine, a marine natural compound,
nd nortriptyline hydrochloride (Oliveira et al., 1990; Diers et al.,
008). Therefore, the FST is generally recommended for a screenl/site, i.c.v.) in combination with a sub-effective dose of AE (3 mg/kg, p.o.) in the
ly). Values are expressed as mean ± S.E.M. (n = 6–7). **P  < 0.01 compared with the
of antidepressant-like effects, and a drug showing positive effects
should then be further tested in the TST (Cryan et al., 2002). It
has also been proposed that the TST is less stressful than the
FST and possesses greater pharmacological sensitivity to lower
doses of antidepressant (Thierry et al., 1986). Accordingly, the
antidepressant-like effect of AE was observed at lower doses in TST
than FST. Moreover, the antidepressant-like effect of 10 mg/kg AE
in the TST was observed until 4 h of administration, an interesting
prolonged effect as compared Tabebuia avellanedae, another plant
extract which presents antidepressant-like effect in TST (Freitas
et al., 2010).
The involvement of NMDA receptors and the l-arginine-NO-
cGMP pathway in antidepressant-like activity of AE and the ability
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Fig. 6. Effect of the pretreatment of mice with sildenaﬁl (5 mg/kg, i.p.) on the anti-
immobility effect of AE (10 mg/kg, p.o.) in the TST (A) and on the number of crossings
in  the open-ﬁeld test (B). Values are expressed as mean ± S.E.M. (n = 6). **P < 0.01
compared with the vehicle-treated control; #P < 0.01 compared with the same group
pretreated with vehicle.
Fig. 7. Ex vivo cell viability analysis in hippocampal slices incubated with glutamate
(Glu, 10 mM)  for 1 h. When present, AE (10, 30 or 100 mg/kg) was  pre-administered
in  mice by gavage (1 h before slices preparation). After this period, incubation media
was withdrawn and replaced for fresh culture medium without Glu and maintained
for additional 6 h. Control group (C, ﬁrst black bar) was  considered as 100% and
other black bars represents cell viability of slices incubated only in culture medium.
White bars represents the cell viability of hippocampal slices subjected to glutamate.
The values represent mean ± SD of at least 5 experiments carried out in triplicates.
Mean signiﬁcantly different from control group (100%); P < 0.05. #Mean signiﬁcantly
different from Glu group; P < 0.05.
Fig. 8. AE treatment increases Akt phosphorylation in hippocampal slices. AE
treatment (10 mg/kg) 1 h before glutamate (10 mM)  signiﬁcantly increases Akt phos-
phorylation at Ser473. (A) Representative Western blot of phosphorylated (p-Akt)
and total content of Akt protein (t-Akt), 56 KDa; (B) The ratio of phosphorylated
Akt/total Akt signal (p-Akt/t-Akt). The optical densities of bands were measured by
Scion Image software. Data in bars are presented as mean ± SD of 4 experiments
carried out in triplicate. *P < 0.05 compared with control (C) group.
of AE treatment (ex vivo experiments) to prevent glutamate-
induced toxicity in hippocampal slices were evaluated.
The involvement of glutamate in the pathophysiology of depres-
sion has been suggested in several studies (for review, see Sanacora
et al., 2008). Increased levels of glutamate in the frontal cortex in
postmortem samples (Hashimoto et al., 2007) and in the plasma of
patients with depression (Mauri et al., 1998) have been reported.
Additionally, NMDA receptor antagonists possess antidepressant
properties and conventional antidepressants have been reported
to reduce the binding, expression and function of NMDA recep-
tors (Skolnick, 1999; Sanacora et al., 2008). The reversal of the
antidepressant-like effect of AE by NMDA suggests its effect is
Fig. 9. AE treatment decreases iNOS expression in hippocampal slices. AE treatment
(10  mg/kg) 1 h before glutamate (10 mM)  signiﬁcantly decreases iNOS expres-
sion. (A) Representative Western blotting of iNOS (130 kDa) and -actin (30 kDa)
immunocontent used as loading control to western blot analysis. (B) The ratio of
iNOS/-actin signal (iNOS/-actin). The optical density of bands was measured by
Scion Image software. Data in bars are presented as mean ± SD of 4 experiments
carried out in triplicate. *P < 0.05 compared with control (C) group.
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ependent on the inhibition of NMDA receptor activation. Besides,
e observed that the co-administration of MK-801 and AE pro-
uced a synergistic antidepressant-like effect. The dose of MK-801
sed in the present study was previously shown to cause no
ffect in the open-ﬁeld test, but it was able to cause a synergis-
ic antidepressant-like effect with folic acid in the FST (Brocardo
t al., 2008). Moreover, it has been shown that ﬂuoxetine and
esipramine inhibit NMDA receptors at clinically relevant con-
entration range (Szasz et al., 2007), a ﬁnding that indicates that
lutamatergic, noradrenergic and serotonergic systems interact in
he mechanism of action of antidepressants (Forray et al., 1999;
aura et al., 2000; Bonanno et al., 2005; Szasz et al., 2007). In addi-
ion, it was recently reported that the antidepressant-like effect of
scitalopram in the FST was reversed by NMDA pretreatment in
ice (Zomkowski et al., 2010).
Due to the existence of data indicating that the NO-cGMP path-
ay is involved in the pathophysiology of depression (Harkin et al.,
999; Kaster et al., 2005; Zomkowski et al., 2010) and also the fact
hat the activation of NMDA receptors is directly associated with
he activation of NOS in the central nervous system, the involve-
ent of this pathway in the antidepressant-like effect of AE was
nvestigated. We  showed that the pretreatment with l-arginine, a
ubstrate for NOS, signiﬁcantly inhibited the anti-immobility effect
aused by AE. Our results are in accordance with studies that have
hown that NOS inhibitors (Wegener et al., 2003) and reduction
f NO levels within the hippocampus can induce antidepressant-
ike effects, thus implicating endogenous hippocampal NO in the
eurobiology of depression (Joca and Guimarães, 2006). Simi-
arly to our results, the antidepressant-like effects of escitalopram,
aroxetine, and venlafaxine were also blocked by pretreatment
ith l-arginine (Dhir and Kulkarni, 2007; Ghasemi et al., 2009;
omkowski et al., 2010). These results indicate that the effect of AE
n the TST may  be dependent on, at least in part, the inhibition of NO
ynthesis.
The assumption that the l-arginine-NO-cGMP pathway is
nvolved in the reduction in the immobility time elicited by AE is
einforced by the ﬁnding that l-NNA (an inhibitor of NOS), ODQ
a selective, irreversible, heme-site inhibitor of sGC) or methylene
lue (an inhibitor of both NOS and sGC), produced a synergis-
ic antidepressant-like effect with AE. Accordingly, it has been
eported that inhibitors of NOS or sGC potentiated the effect of
denosine, venlaxine (Kaster et al., 2005; Dhir and Kulkarni, 2007),
scitalopram and memantine (Almeida et al., 2006; Zomkowski
t al., 2010) in the FST. Hence, our results also suggest that the
ntidepressant-like effect of AE may  be mediated through the
eduction of cGMP, as a consequence of the reduction of NO syn-
hesis, reinforcing the notion that cGMP is an important molecular
arget for antidepressant action.
Noteworthy, the reversal of the antidepressant-like effect of AE
aused by pretreatment with sildenaﬁl, a selective PDE5 inhibitor,
urther indicates that AE exerts its effect in the TST by decreasing
GMP levels. The intracellular cGMP concentrations are regulated
ot only by sGC, but also by PDE, which catalyses the hydroly-
is of the second messengers cAMP and cGMP. The duration and
agnitude of a NO-induced cGMP signal are determined by the
ctivity of PDE5 (Beavo, 1995). Accordingly, the antidepressant-like
ffect of memantine (Almeida et al., 2006), venlafaxine (Dhir and
ulkarni, 2007), folic acid (Brocardo et al., 2008), and escitalopram
Zomkowski et al., 2010) was prevented by sildenaﬁl.
Moreover, the results obtained in the ex vivo experiments with
ippocampal slices show that AE exerts neuroprotection against
he glutamate excitotoxicity. Hippocampal slices exposed to 10 mM
lutamate presented reduced cell viability, which was  not observed
n slices prepared from mice previously treated with AE (10 mg/kg,
.o.). According to Molz et al. (2008),  glutamate at this concen-macology 137 (2011) 864– 874
tration causes hippocampal cells death by apoptosis, which was
completely blocked by MK-801.
Several signaling pathways have been reported to be involved
in the mechanism of action of neuroprotective agents, with spe-
cial attention to the phosphoinositide 3-kinase (PI3K)/Akt signaling
pathway. Akt is a serine–threonine kinase activated by PI3K phos-
phorylation implicated in cell growth, migration, and survival
(Cantley, 2002), and directly related to neuroprotection against
glutamate-induced toxicity (Piermartiri et al., 2009). In the present
study, the neuroprotection afforded by AE (10 mg/kg) against exci-
totoxicity seems to be mediated by activation of Akt signaling and
recovery of cell viability in hippocampal slices. In addition, Akt sig-
naling has been shown to be implicated in the mechanism of action
of antidepressant drugs (Beaulieu et al., 2009).
Furthermore, we observed that glutamate (10 mM)  also
increased the iNOS expression in hippocampal slices. Noteworthy,
this effect was  not observed in slices prepared from mice previ-
ously treated with AE. Since AE is rich in kauranes, ﬂavonoids,
and phenylethanoids (Silva et al., 2006) and possesses antioxidant
activity (Rosas-Romero and Saavedra, 2005) we cannot rule out
an action of these molecules in the mechanism of neuroprotec-
tion afforded by AE and further investigations will be carried out to
clarify this issue.
Therefore, considering the effects of AE herein shown, it is fea-
sible to suggest that the antidepressant-like action of AE might be
related to its neuroprotective action in the hippocampus, which
is consistent with the relationship between hippocampal dam-
age and depressive disorders (Sapolsky, 2000). Altogether, our
results positively support the traditional use of Aloysia gratissima in
South America folk medicine. Studies are being carried out in our
laboratories to discriminate additional activities of aqueous extract
and the constituents of Aloysia gratissima upon the central nervous
system, as well as to clarify their mechanisms of action.
5. Conclusion
The results of the present study revealed that AE exerted an
antidepressant-like effect in the FST and TST. In addition, the
antidepressant-like effect was  shown to be dependent on its
interaction with NMDA receptors and l-arginine-NO-cGMP path-
way. Moreover, AE protected hippocampal slices against glutamate
excitotoxicity through activation of Akt pathway and decrease of
iNOS expression. Altogether, the results indicate that Aloysia gratis-
sima may  be of interest as a plant species source for therapeutic
agent for the treatment of depressive disorders and neurodegener-
ation.
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